The U.S. Food and Drug Administration recently gave the go-ahead to two new drugs, Xeljanz and Quillivant XR, to treat rheumatoid arthritis and Attention Deficit Hyperactivity Disorder, respectively, the manufacturing companies announced in separate statements.
The chain of rating downgrades affecting Puerto Rico’s credit added yet another link Monday, when Moody's Investors Service cut the rating on approximately $8.0 billion of outstanding power revenue bonds held by Puerto Rico Electric Power Authority's to Baa2 from Baa1.
As the year comes to a close, Puerto Rico’s bankruptcy filings appear to be keeping the downward trend that has prevailed throughout most of 2012. Filings through November were down 8 percent year-over-year, with 9,532 cases on record at the U.S. Bankruptcy Court.
A Dow Jones/Factiva content provider since 2014
Subscribe to our Dollars & Sense podcast!
